Symbols / KLRA Stock $24.30 -3.65% Kailera Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
KLRA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Stock Fundamentals
Scroll to Statements
Market Cap 3.15B Enterprise Value — Income -148.96M Sales — Book/sh — Cash/sh —
Dividend Yield — Payout 0.00% Employees 145 IPO — P/E — Forward P/E —
PEG — P/S — P/B — P/C — EV/EBITDA — EV/Sales —
Quick Ratio 11.83 Current Ratio 12.02 Debt/Eq — LT Debt/Eq — EPS (ttm) -1.26 EPS next Y —
EPS Growth — Revenue Growth — Earnings — ROA -22.73% ROE -36.90% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 129.54M Shs Float 9.71K Short Float —
Short Ratio — Short Interest — 52W High 28.23 52W Low 23.65 Beta — Avg Volume 2.80M
Volume 888.29K Target Price — Recom None Prev Close $25.22 Price $24.30 Change -3.65%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$24.30
Latest analyst target
3. DCF / Fair value
$-8.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$24.30
Low
—
High
—
Mean
—
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31
Total Revenue
0.00
Operating Revenue
0.00
Operating Expense
158.34
Research And Development
109.11
Selling General And Administration
49.23
General And Administrative Expense
49.23
Other Gand A
49.23
Total Expenses
158.34
Operating Income
-158.34
Total Operating Income As Reported
-158.34
EBITDA
-158.03
Normalized EBITDA
-158.03
Reconciled Depreciation
0.31
EBIT
-158.34
Total Unusual Items
0.00
Total Unusual Items Excluding Goodwill
0.00
Special Income Charges
0.00
Net Income
-148.96
Pretax Income
-148.96
Net Non Operating Interest Income Expense
11.05
Net Interest Income
11.05
Interest Income Non Operating
11.05
Interest Income
11.05
Other Income Expense
-1.66
Other Non Operating Income Expenses
-1.66
Gain On Sale Of Business
0.00
Tax Rate For Calcs
0.00
Tax Effect Of Unusual Items
0.00
Net Income Including Noncontrolling Interests
-148.96
Net Income From Continuing Operation Net Minority Interest
-148.96
Net Income From Continuing And Discontinued Operation
-148.96
Net Income Continuous Operations
-148.96
Normalized Income
-148.96
Net Income Common Stockholders
-148.96
Diluted NI Availto Com Stockholders
-148.96
Line Item Trend 2025-12-31 2024-12-31
Total Assets
692.29
+287.96%
178.44
Current Assets
557.54
+213.91%
177.61
Cash Cash Equivalents And Short Term Investments
546.06
+211.71%
175.18
Cash And Cash Equivalents
160.27
-8.51%
175.18
Other Short Term Investments
385.79
0.00
Receivables
2.73
0.00
Accrued Interest Receivable
2.73
0.00
Prepaid Assets
7.52
+259.90%
2.09
Other Current Assets
1.23
+259.77%
0.34
Total Non Current Assets
134.76
+16057.91%
0.83
Net PPE
12.42
+1726.18%
0.68
Gross PPE
12.52
+1607.78%
0.73
Accumulated Depreciation
-0.10
-88.68%
-0.05
Properties
0.00
0.00
Machinery Furniture Equipment
1.49
+469.85%
0.26
Other Properties
10.46
+2121.44%
0.47
Leases
0.56
0.00
Investments And Advances
106.67
0.00
Non Current Prepaid Assets
12.19
0.00
Other Non Current Assets
3.48
+2161.04%
0.15
Total Liabilities Net Minority Interest
1,048.75
+164.02%
397.22
Current Liabilities
46.41
+571.47%
6.91
Payables And Accrued Expenses
35.40
+1362.60%
2.42
Payables
7.53
+274.95%
2.01
Accounts Payable
7.53
+274.95%
2.01
Current Accrued Expenses
27.87
+6663.59%
0.41
Pensionand Other Post Retirement Benefit Plans Current
9.05
+396.93%
1.82
Current Debt And Capital Lease Obligation
1.04
+104.32%
0.51
Current Capital Lease Obligation
1.04
+104.32%
0.51
Other Current Liabilities
0.92
-57.59%
2.16
Total Non Current Liabilities Net Minority Interest
1,002.35
+156.81%
390.31
Long Term Debt And Capital Lease Obligation
9.71
0.00
Long Term Capital Lease Obligation
9.71
0.00
Other Non Current Liabilities
0.27
—
Preferred Securities Outside Stock Equity
992.36
+154.25%
390.31
Stockholders Equity
-356.46
-62.94%
-218.77
Common Stock Equity
-356.46
-62.94%
-218.77
Capital Stock
0.00
0.00
Common Stock
0.00
0.00
Additional Paid In Capital
11.98
+1173.22%
0.94
Retained Earnings
-368.67
-67.80%
-219.71
Gains Losses Not Affecting Retained Earnings
0.23
0.00
Other Equity Adjustments
0.23
—
Total Equity Gross Minority Interest
-356.46
-62.94%
-218.77
Total Capitalization
-356.46
-62.94%
-218.77
Working Capital
511.13
+199.43%
170.70
Invested Capital
-356.46
-62.94%
-218.77
Total Debt
10.75
+2012.57%
0.51
Capital Lease Obligations
10.75
+2012.57%
0.51
Net Tangible Assets
-356.46
-62.94%
-218.77
Tangible Book Value
-356.46
-62.94%
-218.77
Available For Sale Securities
106.67
—
Investmentin Financial Assets
106.67
0.00
Line Item Trend 2025-12-31
Operating Cash Flow
-120.21
Cash Flow From Continuing Operating Activities
-120.21
Net Income From Continuing Operations
-148.96
Depreciation Amortization Depletion
0.31
Depreciation And Amortization
0.31
Other Non Cash Items
-1.07
Stock Based Compensation
10.94
Unrealized Gain Loss On Investment Securities
1.78
Change In Working Capital
16.78
Change In Prepaid Assets
-20.94
Change In Payables And Accrued Expense
37.99
Change In Accrued Expense
33.30
Change In Payable
4.69
Change In Account Payable
4.69
Change In Other Current Assets
-0.14
Change In Other Current Liabilities
-0.13
Investing Cash Flow
-492.60
Cash Flow From Continuing Investing Activities
-492.60
Net PPE Purchase And Sale
-2.09
Purchase Of PPE
-2.09
Capital Expenditure
-2.09
Net Investment Purchase And Sale
-490.51
Purchase Of Investment
-632.16
Sale Of Investment
141.65
Financing Cash Flow
598.66
Cash Flow From Continuing Financing Activities
598.66
Net Issuance Payments Of Debt
100.00
Issuance Of Debt
100.00
Long Term Debt Issuance
100.00
Net Long Term Debt Issuance
100.00
Net Common Stock Issuance
498.87
Proceeds From Stock Option Exercised
0.10
Net Other Financing Charges
-0.32
Changes In Cash
-14.15
Beginning Cash Position
175.18
End Cash Position
161.03
Free Cash Flow
-122.30
Common Stock Issuance
498.87
Issuance Of Capital Stock
498.87
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category